Covid-19 vaccine developers stand out as global drug stocks tread water in the first quarter.
It's official: dramatic share price jumps in response to clinical data have become more common.
Aclaris takes a step towards an oral rheumatoid arthritis therapy.
Daiichi Sankyo’s incredible stock market performance stands out amid the usual mixed bag of fallers and risers among biopharma’s mid- and small caps.
Concert believes that high-dose data with CTP-543 will help it challenge Pfizer, but patent questions still loom large.
Concert hopes to give Pfizer a run for its money in alopecia, while Reata looks to continue its renaissance with more Phoenix data.